Goldman Sachs reiterated its Sell rating on Itron ITRI. The company is having a rough time and it has started a restructuring plan. Goldman does not seem to be persuaded that the company's plan will produce immediate results, however.
In a research report published today, Goldman states, "We rate ITRI shares Sell with 16% downside
to our $45 12-month target and believe execution is needed to increase
confidence in the targeted five-year reset. We believe these aspirational
goals will require a delicate balance between: (1) managing down costs in
its larger base of 'book & ship' meters as volumes and ASPs decline; while
(2) building market share in new regions/products. With the ramp in
European AMI likely to occur in 2013+, we see limited EPS upside and
reasons for those not currently involved to invest at these levels. Longer
term, we remained focused on the impact on ROIC as Itron pursues an
aggressive growth plan via organic and substantial inorganic growth.
Recent industry M&A supports the company's view that financial strength
matters more as the industry grows."
At the moment, Goldman has a price target of $45 on Itron. On Thursday, Itron added 0.93% to its value to close the day at $53.42. Its shares lost all of yesterday's gains in today's pre-market trading, however, falling $2.98% to $51.83.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in